From GlobeNewswire:

Molecular Partners AG, a biotech company developing cutting-edge DARPin therapeutics, is set to unveil its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference this week. Some updates on their programs include positive initial data from MP0533 trial for relapsed/refractory AML and MDS/AML patients, and a strategic collaboration with Orano Med for co-development of Radio-DARPin Therapies for patients with solid tumors. The company also introduced its first program from the Switch-DARPin platform, allowing local immune cell activation for targeted killing of hematopoietic stem cells in patients with AML. Additionally, they provided updates on the recent cKIT x CD16a x CD47 Switch-DARPin and their financial guidance for 2024. These developments position Molecular Partners to make an impact on various therapeutic areas.



Read more: Molecular Partners Provides Updates at 42nd Annual J.P.